|13.83||-0.39 / -2.74%|
Data as of 4:00pm ET
|13.83||0.00 / 0.00%|
The 6 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 14.50, with a high estimate of 24.00 and a low estimate of 4.50. The median estimate represents a +4.84% increase from the last price of 13.83.
The current consensus among 6 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.